- Bausch + Lomb to launch Phase 3 trial of dry‑eye drop after Phase 2 missBausch + Lomb announced plans to move its dual‑action dry‑eye drop into a Phase 3 study. The decision follows a Phase 2 trial that did not meet its primary endpoint. CEO Brent Saunders said the r…
- Why Biopharma Executives Should Hire an ‘Implementer’ to Turn Ideas into ActionLeadership Lab is a new column aimed at biopharma leaders facing real‑world pressures. In the opening piece, Michael Pietrack of Kaye/Bassman International argues that the most valuable hire for an…